Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer

Genetic Testing and Molecular Biomarkers

Volumn 14, Issue 4, 2010, Pages 515-526

  Guénard, Frédéric ^a   Pedneault, Christopher St Laurent ^a   Ouellette, Geneviève ^a   Labrie, Yvan ^a   Simard, Jacques ^a   Durocher, Francine ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; PROTEIN KINASE LKB1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PALB2 GENE; PEUTZ JEGHERS SYNDROME; SEQUENCE ANALYSIS;

ADULT; AGED; BREAST NEOPLASMS; CANADA; CARCINOMA; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; QUEBEC; RISK; TUMOR SUPPRESSOR PROTEINS;

EID: 77955861787     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0027     Document Type: Article

References (51)

1. Ahn J, Urist M, Prives C (2004) The Chk2 protein kinase. DNA Repair (Amst) 3:1039-1047.
2. Alessi DR, Sakamoto K, Bayascas JR (2006) LKB1-dependent signaling pathways. Annu Rev Biochem 75:137-163.
3. Ameziane N, van den Ouweland AM, Adank MA et al. (2009) Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer. Breast Cancer Res Treat 118:651-653.
4. Amos CI, Keitheri-Cheteri MB, Sabripour M et al. (2004) Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet 41:327-333.
5. Antoniou A, Pharoah PD, Narod S et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130.
6. Antoniou AC, Easton DF (2003) Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol 25:190-202.
7. Aretz S, Stienen D, Uhlhaas S et al. (2005) High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 26:513-519.
8. Bahassi EM, Ovesen JL, Riesenberg AL et al. (2008) The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 27:3977-3985.
9. Bell DW, Varley JM, Szydlo TE et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531.
10. Bignell GR, Barfoot R, Seal S et al. (1998) Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res 58:1384-1386.
11. Cao AY, Huang J, Hu Z et al. (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114:457-462.
12. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175-1182.
13. Chen J, Lindblom A (2000) Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. Clin Genet 57:394-397.
14. Chen P, Liang J, Wang Z et al. (2008) Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res 14:5931-5937.
15. Dong SM, Kim KM, Kim SY et al. (1998) Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers syndrome gene in left-sided colon cancer. Cancer Res 58:3787-3790.
16. Dufault MR, Betz B, Wappenschmidt B et al. (2004) Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 110:320-325.
17. Durocher F, Labrie Y, Soucy P et al. (2006) Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 6:230.
18. Erkko H, Dowty JG, Nikkilä J et al. (2008) Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 14:4667-4671.
19. Erkko H, Xia B, Nikkilä J et al. (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316-319.
20. Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937-948.
21. Forster LF, Defres S, Goudie DR et al. (2000) An investigation of the Peutz-Jeghers gene (LKB1) in sporadic breast and colon cancers. J Clin Pathol 53:791-793.
22. Foulkes WD, Ghadirian P, Akbari MR et al. (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9:R83.
23. García MJ, Fernández V, Osorio A et al. (2009) Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/ 2-negative Spanish breast cancer families. Breast Cancer Res Treat 113:545-551.
24. Ghadirian P, Robidoux A, Zhang P et al. (2009) The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet 76:421-426.
25. Giardiello FM, Brensinger JD, Tersmette AC et al. (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119:1447-1453.
26. Guénard F, Labrie Y, Ouellette G et al. (2007) Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. Fam Cancer 6:483-490.
27. Hearle N, Schumacher V, Menko FH et al. (2006) Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12:3209-3215.
28. Launonen V (2005) Mutations in the human LKB1/STK11 gene. Hum Mutat 26:291-297.
29. Launonen V, Avizienyte E, Loukola A et al. (2000) No evidence of Peutz-Jeghers syndrome gene LKB1 involvement in leftsided colorectal carcinomas. Cancer Res 60:546-548.
30. Li FP, Fraumeni JF, Jr. (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747-752.
31. Mehenni H, Resta N, Park JG et al. (2006) Cancer risk in LKB1 germline mutation carriers. Gut 55:984-990.
32. Meijers-Heijboer H, van den Ouweland A, Klijn J et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59.
33. Moisan AM, Fortin J, Dumont M et al. (2006) No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. Genet Test 10: 104-115.
34. Novak DJ, Chen LQ, Ghadirian P et al. (2008) Identification of a novelCHEK2variant andassessmentof its contributiontothe risk of breast cancer in French Canadian women. BMC Cancer 8:239.
35. Offit K, Pierce H, Kirchhoff T et al. (2003) Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 4:1.
36. Pylkä s K, Erkko H, Nikkilä J et al. (2008) Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 8:146.
37. Rahman N, Seal S, Thompson D et al. (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165-167.
38. Reid S, Schindler D, Hanenberg H et al. (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162-164.
39. Simard J, Dumont M, Moisan AM et al. (2007) Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet 44:107-121.
40. Sluiter M, Mew S, van Rensburg EJ (2009) PALB2 sequence variants in young South African breast cancer patients. Fam Cancer 8:347-353.
41. Sodha N, Houlston RS, Bullock S et al. (2002) Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum Mutat 20:460-462.
42. Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17-22.
43. Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 106:7155-7160.
44. Tischkowitz M, Xia B, Sabbaghian N et al. (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 104:6788-6793.
45. Vahteristo P, Bartkova J, Eerola H et al. (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432-438.
46. Volikos E, Robinson J, Aittomä ki K et al. (2006) LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet 43:e18.
47. Weischer M, Bojesen SE, Ellervik C et al. (2008) CHEK2*1100-delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26:542-548.
48. Wu X, Webster SR, Chen J (2001) Characterization of tumorassociated Chk2 mutations. J Biol Chem 276:2971-2974.
49. Xia B, Dorsman JC, Ameziane N et al. (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159-161.
50. Xia B, Sheng Q, Nakanishi K et al. (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719-729.
51. Zhang F, Ma J, Wu J et al. (2009) PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 19:524-529.